We received early access to the newest releases of
Introduction
The exome is considered to be the most functionally relevant (and technically accessible) 1%-2% of the genome as it is ideally composed of all exons of all annotated coding genes. Target sizes start from 34 Mb (Illumina Rapid Exome, Illumina, San Diego, CA, USA) up to 64 Mb (NimbleGen EZ exome v3). The NimbleGen EZ exome v3 and other large exome products also include some non-coding sequence like untranslated region (UTRs). If standard thresholds are applied (70-100 × coverage on average, > 80% of the target covered by at least 30 × ), the sequencing effort for whole exome sequencing (WES) is about 7% compared to whole genome sequencing (WGS) approaches aiming at 30 × coverage on average. Sequencing costs for WES including the enrichment process are ca. 1/3 of the costs for WGS. This is due to the fact that new high-throughput sequencing factories are available for human WGS (Illumina HiSeq X Five or Ten Systems, comprised of five or ten HiSeq4000 with the application limited to genomes and comparably less expensive consumables), which drastically lowered the price for genomes whereas the development of equipment for core facilities and single institutes was less dynamic keeping the price for exomes nearly constant.
Due to their smaller size, WES data are by far easier to handle as it allows faster computational analysis, and fewer computational resources are required compared to WGS. A high rate of discoveries of new disease-associated genes in Mendelian diseases over the last couple of years is mainly a result of WES (Zhang, 2014; Filges and Friedman, 2015; Smedley and Robinson, 2015) . However, the enrichment process itself needs more hands-on time as well as technical expertise than WGS and adds one or two additional days to the workflow of any individual exome. Further drawbacks of WES analysis are the ongoing difficulties in detecting copy-number variations (CNVs) and, of course, the inability to detect single nucleotide changes or structural variants outside the targeted regions.
All relevant capture products available today use an in-solution hybridization capture enrichment approach, which shows the highest enrichment efficiency for large targets like exomes and enables the detection of at least some structural variations (e.g. if one or both breakpoints are located within the coding sequence; Altmüller et al., 2014; Beleggia et al., 2015) . It is also more sensitive to subclonal events than amplicon-based technologies because of the underlying shot-gun library preparation and the ability to exclude PCR duplicates. Exome products differ in number, size, and kind of baits (RNA or DNA). The library preparation and enrichment protocols also differ slightly, and the insert sizes and pooling strategies have some impact on the complete pipeline from wet lab to data analysis (Frommolt et al., 2012) . Several exome product comparisons can be found in the literature that address the newest exome targets of their time (Asan et al., 2011; Clark et al., 2011; Sulonen et al., 2011; Chilamakuri et al., 2014; Shigemizu et al., 2015; Zhang et al., 2015) . Commercial exome product vendors steadily improve their target with respect to both evolving human genome builds and annotations, and technical developments that facilitate lab processes and increase the percentage of on-target sequence and the evenness and completeness of coverage.
In this review, 'enrichment performance' is used as an umbrella term, consisting of three independent parts, namely completeness, efficiency, and evenness. Completeness includes both the choice and size of the target, and, for an existing target, the drop-off rate (target sequence with < 2 × coverage) that can be observed. Efficiency is of major economic value, as it gives the percentage of sequencing effort that leads to target coverage. Important numbers to compare for efficiency are number of unique reads (after removal of duplicates) and the mean coverage that can be achieved with a certain number of unique reads (percentage of reads on target, which then leads to the mean coverage). Evenness of coverage distribution is the main quality indicator which can be evaluated best by relating the percentage of target that is covered more than 30 × with the mean coverage (e.g. 85% of target with at least 30 × indicates a good evenness if it is produced with 70 × average coverage and a poor one if it is produced with 200 × average coverage). Normalized data sets allow an easy comparison of evenness using only the percentage of target coverage 30 × value.
In this review, we evaluate two new releases, namely the Agilent v6 exome and the NimbleGen MedExome, and compare their performance. As a next-generation sequencing (NGS) core facility with a focus on human genetics and cancer genomics applications, we have a history of sequencing several thousands of exomes of earlier versions of both vendors. In our opinion, both of them have previously proven to sell high quality WES products and provide reliable support. In general, we trusted that both products would show improvements to some extent compared to the older versions. Therefore, we decided to only compare these two new products and sequenced and compared the data in (i) raw output format, (ii) normalized format taking into account the different target sizes, and (iii) trimmed to 2 × 75 bp reads to estimate to what extent pipeline changes (e.g. from HiSeq 2000/2500 to HiSeq 4000) would influence the performance. As these general statistics are still somewhat superficial, we decided (iv) to provide a deeper look and more intuitive perception by a detailed comparison on a subgroup of frequently mutated and newly found disease-relevant genes listed in 'The Deciphering Developmental Disorders Study' published recently (Fitzgerald et al., 2015) .
Results and discussion

Comparison of original data
On average, we produced WES data sets of 97.7 million (M) 100 bp reads corresponding to 9.8 Gb for the Agilent v6 Exome and 106.8 M 100 bp reads corresponding to 10.7 Gb for the NimbleGen MedExome. One pool of four exomes ran on one lane of a Hiseq2000 flow cell. Each sample was marked with a unique DNA barcode which is sequenced in a special 'index' read and used to separate the reads into individual data files for all samples. When too many sequencing errors occur in the index read, the read cannot be assigned to its sample and is collected in an undetermined indices data file. We lost 1.3-1.5 Gb per lane of undetermined indices for the Agilent exomes and a little lower 1.1-1.2 Gb per lane for the MedExome, respectively. This does not fully explain the difference in data generation per exome (which is mainly caused by different sequencing cluster densities) but is a general observation seen with different index length (6 nucleotides (nt) for NimbleGen, 8 nt for Agilent). Long index sequences purify the exome files and allow a higher multiplexing degree but -if overacted -produce more waste than necessary both with the cycles spent on them and with the higher number of undetermined index reads.
The approximately same number of reads produced higher average coverage for NimbleGen exomes. This was expected because of the lower target size (47 Mb vs. 61 Mb). For an Agilent exome, 97.7 M total reads with 100 bp read length correspond to 9.77 Gb of sequence data. Of these, 89.0%, and of this 94.3% mapped to the genome. To generate a mean coverage of 98.4 × for a 61 Mb target, 6.0 Gb sequence data are needed, which means that 73% of mapped unique reads aligned to the target. For the MedExome, 63% of all mapped unique reads align on the NimbleGen target. A striking and most relevant result was that the nearly same numbers of reads yielded a higher fraction of the target region to be covered more than 30 × with Agilent compared to NimbleGen (89.68% vs. 87.63%). This difference in enrichment evenness is enormous taking into account that the Agilent target is 29.7% larger in size than the NimbleGen target. The reason for this difference is most probably a more uniform and balanced overall coverage achieved by Agilent (also smaller difference between percentages of target sequence covered at least 10-30 × , Figure 1 ). For us, the target covered by at least 30 × value is the most important one as it defines the percentage of the target, where safe calling of heterozygous variants is possible.
When looking at the percentage of the target with at least 10 × coverage (a common threshold for filter criteria), NimbleGen seems to perform slightly better than Agilent, and for the 2 × values (also called drop-off rate), it even turns out that only about 1.5% of target is missed with the MedExome compared to 2.5% with the Agilent v6. Considering the different exome target sizes, we end up with analyzable (i.e. covered by at least 10 × ) 96.6% of 61 Mb with Agilent compared to 96.8% of 47 Mb with NimbleGen applying the same sequencing effort. The numbers shown in Table 1 are obviously of high concordance within the two groups and would even allow us to assign data of unknown origin to the specific enrichment product. We feel confident that the numbers of exomes compared in this test were sufficiently high to draw the conclusions arrived at above.
Comparison of normalized data
In order to perform an objective and fair efficiency and evenness comparison concerning the different target sizes, we normalized the data to the same amount of reads (Table 1 ) and normalized (Table 2) data. After the removal of PCR duplicates, we observed 89.8% unique reads with Agilent compared to 91.8% unique reads with NimbleGen. As the sequencing effort per target size was the same here and the number of PCR cycles was smaller for Agilent, (NimbleGen MedExome: PCR pre-capture: 8 cycles, PCR post-capture: 18 cycles; Agilent v6, 200 ng DNA input: PCR pre-capture: 10 cycles, PCR post-capture: 12 cycles), this difference was probably due to the different amount of input DNA, which is associated with library complexity. As the NimbleGen protocol ideally starts with 1 μg of DNA, we had to choose between the 200 ng and the 3 μg protocol for Agilent. Based on our experience, about half of our collaborators do not have 3 μg of DNA available (or they are not willing to expend so much DNA on the exome analysis), we decided to go for the most realistic 200 ng approach. Low-input protocols are of course advantageous per se and make some projects feasible at all, but regarding the number of duplicates, exome projects would certainly benefit from a higher input amount of DNA (and therefore lower number of PCR cycles).
In the normalized data sets (Table 2, Figure 1 ), the difference in enrichment performance became more apparent: Agilent's newest product outperforms the NimbleGen MedExome both in terms of average coverage (higher efficiency) and percentage of bases covered by at least 30 × (better evenness). This difference in reads on target became obvious by a difference in average coverage of 9.7 × . In contrast, the drop-off rate was smaller with the MedExome. Having done several thousands of NimbleGen v2 exomes with our current pipeline and a 5/lane loading on an Illumina HiSeq2000 sequencer, we would have to face the fact that with the increase from 44 Mb to 47 Mb with the MedExome, generation of 7 Gb/exome (roughly the same as shown with the normalized data set) would no longer be sufficient to reach the 80% threshold of target covered by at least 30 × . 
Comparison of trimmed data
On the basis of the original data sets shown in Table 1 , we generated reduced data sets by trimming all reads to 2 × 75 bp to simulate the performance obtained with the common read length provided by the new Illumina HiSeq 4000 sequencer. Concerning read length, it is important to mention that the libraries have a characteristic insert size differing in both protocols, namely 205 bp for NimbleGen and 180 bp for Agilent in our hands (measured in the final library quality control taking the peak value minus length of adapter sequence, data not shown). Insert sizes in this range make sense of course, as the average human exon is about 200 bp long and longer inserts would directly cause a higher percentage of off-target sequence. A 2 × 100 bp read length is obviously an ideal and cost-efficient read length for NimbleGen exomes. Using the maximum read length suitable for the insert size has benefits for the price (which is lower per Gb for 2 × 100 bp compared to 2 × 75 bp) and for the alignment performance.
Longer inserts (independent of the read length) should also be helpful to identify structural variations, but this point is not easy to prove as the number of structural variants identified in WES is still small. Generation of 2 × 100 bp reads with 180 bp inserts for Agilent resulted in some overproduction. If both reads of a pair were considered as single reads in the analysis (which is a common procedure and also applied in our coverage computations), mean coverage would be overestimated. If, for example, Agilent exomes run on a HiSeq 2500 sequencer with v4 chemistry and a 2 × 125 bp read length, there would be an overlap of about 70 bp in the middle of each fragment leading to 28% overestimation of average coverage. Overlapping reads can also be a source of false positives variant calls if no consensus sequence is generated from the overlapping part. In this case, PCR artifacts could be called as single nucleotide variants (SNVs), in case their forward and backward reads support a variant in regions with comparatively low coverage (personal observation, data not shown).
In summary, the new read length of 2 × 75 bp for the HiSeq 4000 could be beneficial for Agilent exomes that are smaller in insert size. By reducing the data set to 3/4 of the original data set with the trimming procedure, the average coverage was also reduced to 3/4 (e.g. from 98.4 × to 72.9 × ). The percentage of mapped unique reads is almost the same for both read lengths, so with the current analysis pipeline, no drawbacks are expected with the reduction of read length.
As discussed before, the 2 × 100 bp read length caused some overestimation of mean coverage for Agilent in the original data sets, because the Agilent libraries have a smaller insert size and the paired-end reads do overlap in a higher proportion compared to the NimbleGen exome. Therefore, independent from the practical considerations, the trimmed data set allows a better comparison of the two exome products, because almost no overlap can be expected with the 2 × 75 bp read length for any of the exomes. Table 3 shows that Agilent's percentage of target region with at least 30 × coverage remains higher after trimming (83.4% vs. 80.8% for NimbleGen). More than 310 M clusters/lane (~620 M total reads) are generated with the Illumina HiSeq 4000 system, which is equivalent to ~47 Gb when performing a 2 × 75 bp paired-end run. This makes a 6/lane allocation feasible for both exome products based on the data shown in Table 3 (nearly 100 M reads/sample give about 83% and 81% of target covered by at least 30 × with Agilent and NimbleGen, respectively).
As another practical aspect, the pre-pooling strategy should be mentioned: for both protocols, pre-pooling of samples before enrichment can be conducted and is supported by the vendors. The difference is that with NimbleGen, customers are able to pool any number of libraries (up to 96; van der Werf et al., 2014), which of course has an enormous impact on costs. For Agilent, XT (individual enrichment) and XT2 (pre-pooling of 8 samples) kits are available, which differ in hands-on time when being processed but are sold for the same price per exome. In total, costs for pre-pooling of 5-6 samples for NimbleGen exomes (fitting on one sequencing lane) and individual preparation of 5-6 exomes with Agilent products are almost the same, and therefore, only quality and practical reasons have to be considered here.
Standard deviation of the number of reads seems to be a little lower with individually enriched Agilent exomes but the difference is only small and the significance limited due to the small number of samples (see Table 1 ). Our personal experience indicates that this becomes more relevant if very heterogeneous DNA from different input material (isolation methods, age, dilution buffers, FFPE, etc.) is processed together. This can increase the standard deviation of data amount per exome dramatically if a prepooling approach is used.
Another quality aspect is the risk of contamination. We observed that pre-pooling, most probably due to template switching in the second PCR reaction, causes a small inter-exome contamination (data not shown; Jun et al., 2012 ). This will probably not lead to discovery of false positives with common coverage and filtering criteria and can also be addressed bioinformatically (Flickinger et al., 2015) , but still, it is at least a flaw and could eventually cause more serious problems if subclonal events (tumors, mosaicism, cfDNAs) are under investigation. For our pipeline, we have chosen to avoid pre-pooling approaches as much as possible and to manage the higher hands-on effort with the help of automation devices.
Comparison of selected genes
The statistics shown so far might be too theoretical and superficial to allow decision making for diagnostic or research exome sequencing pipelines. Therefore, we decided to present some coverage statistics based on individually selected genes, extracted from a paper published recently (Fitzgerald et al., 2015) . The enrichment products in this comparison are again the two new exome products reviewed so far and in addition to that a commonly used diagnostic tool from Illumina, the TruSight One panel that we call 'the Mendeliome'. This panel analyzes 4813 genes with known clinical relevance and is therefore an interesting counterpart to the NimbleGen MedExome. To make a fair comparison and avoid any bias that may have been introduced by choosing our in-house sample preparation protocols, we selected three data sets, one from each enrichment product, which showed the same quality concerning the percentage of their target that is covered by at least 30 × . Table 4 shows the basic statistics of the three exemplary data sets. Although we cannot completely exclude that a single missing exon could have a biological background, the majority of coverage differences in this comparison should be attributed to the differences in enrichment completeness and evenness.
We compiled two groups of genes from the study published in 'The Deciphering Developmental Disorders Study' recently (Fitzgerald et al., 2015) : one consisted of those well-known genes, which were found with de novo mutations in 0.5%-1% of patients with developmental disorders as described in the paper, namely ARID1B, SATB2, SYNGAP1, ANKRD11, SCN1A, DYRK1A, STXBP1, and MED13L. For all these well-known genes, all three enrichment products give satisfactory coverage along most coding exons (Figure 2) . As a general observation, the Illumina TruSight One panel does not target those exons, which are only transcribed but not translated (Figure 2 , see colored bars at the bottom, for example marked with a box in ARID1B). By visual judgment, a slightly higher average coverage could be seen for the MedExome, which is supported by the data shown in Table 5 (see, e.g. box in MED13L). Still, even when comparing exon coverage in one and the same gene, the best enrichment product for one exon might not be the best performing one for the neighboring exon. Looking, e.g. at the GC rich 1st exon of SYNGAP1, we saw no coverage at all for all the three enrichment products, so even if products are improved compared to their last versions, none of them are perfect.
The second group of genes was extracted from Table 2 of the same paper, which lists newly found but also recurrently mutated genes, namely COL4A3BP, PPP2R5D, ADNP, POGZ, PPP2R1A, DDX3X, CHAMP1, BCL11A, and PURA (Figure 3 ). The first expected but striking result was that five of these nine novel disease-associated genes were not covered at all by Illumina TruSight One (DDX3X, COL4A3BP, CHAMP1, PURA, and PPP2R5D). Of course, the designers of this or any other disease gene panel cannot forecast which genes will be associated with diseases in the future. Still, this result indicates the absolute need of highly frequent updates for standard gene panels. Both exomes again decently covered most of the exons of all novel genes investigated, but now with a higher average coverage visible for most of them in the Agilent product. This concerns again DDX3X, COL4A3BP, CHAMP1, PURA, and PPP2R5D, which is an indication that these genes have not been associated with disease phenotypes before. Assuming that this observation is representative for about 75%-85% of genes in the exome not listed as diseaseassociated genes to date, the generally higher enrichment evenness of Agilent v6, as discussed earlier, is explained.
To give a more objective basis for the comparison of these two groups of genes, we list for all three products the number of exons in each gene that contain nucleotides below 30 × coverage (considered as 'not-perfect' exons) and the number of exons that contain nucleotides below 20 × coverage (considered as 'not-OK', Table 5 ). Performances of well-known and newly described genes at the exon level.
Illumina TruSight One Agilent v6
NimbleGen MedExome n nt < 30 × nt < 20 × n nt < 30 × nt < 20 × n nt < 30 × nt < 20 × Well-known  ARID1B  39  4  2  39  8  2  39  2  2  SATB2  20  10  6  20  6  4  20  2  2  SYNGAP1  19  6  3  19  7  4  19  2  2  ANKRD11  11  3  1  11  3  2  11  1  1  SCN1A  78  27  12  78  36  12  78  23  12  DYRK1A  42  8  0  42  14  8  42  8  4  STXBP1  48  13  2  48  3  0  48  2  0  MED13L  31  11  4  31  8  1  31  1  1  ∑  288  82  30  288  85  33  288  41  24  %  28  10  30  11  14  8   New  COL4A3BP  51  51  51  51  16  10  51  33  21  PPP2R5D  46  46  46  46  6  1  46  5  0  ADNP  3  1  1  3  1  1  3  1  0  POGZ  86  20  10  86  14  9  86  20  15  PPP2R1A  15  0  0  15  2  0  15  1  1  DDX3X  33  33  29  33  10  8  33  21  9  CHAMP1  1  1  1  1  0  0  1  0  0  BCL11A  14  0  0 Figures 2 and 3 , we saw considerably sharper peaks for Agilent, which is responsible for the good sequence-on-target performance, but may lead to oversight of variants close to the exon-intron boundaries (e.g. boxes in Figure 2 for ANKRD11 and DYRK1A). Agilent claimed to address especially the drop-off in coverage at the edges of targets with this new version, but compared to the competitors, the drop-off at the edges is still present. For the 250 exons of the newly described genes, only the two exome products could be compared for the obvious reasons described before. With only 11%-12% of not-OK exons in both gene sets, the overall performance of Agilent's new enrichment kit seems to be quite balanced and reliable, whereas 34% of 'not-perfect' and 20% of 'not-OK' exons shown by the NimbleGen product in the newly described genes is less complete. Therefore, the NimbleGen MedExome is probably less powerful for identifying new genes associated with diseases than the Agilent exome.
Conclusion
When deciding on an exome product, the very simple question of a customer often is do we want to pay more money for a larger sequencing effort in order to evaluate a more comprehensive target size? For the new products that we compared in this review, the answer is clear: we do not have to, we get the larger target size with the same sequencing effort. The Agilent v6 with a 61 Mb target outperforms the NimbleGen's MedExome both in efficiency and evenness of coverage distribution. Drawbacks are still present: target coverage is never perfect and also not complete. But in our opinion, the new Agilent v6 product is more efficient and more comprehensive, and therefore, at least in our hands, will be the most successful exome in research settings aiming to identify novel disease-associated genes.
In contrast, if the exome pipeline is mainly used in a diagnostic setting, we see advantages for the new NimbleGen MedExome. The superior coverage in genes of high clinical relevance likely allows for a better detection of relevant, disease-causing mutations than with other exome products. Gene panels have some advantages concerning costs and turnaround time, but if not regularly updated on gene content, will become 'second choice' products in short time. The MedExome covers this niche as it consists of an integrated, highly efficient ' Mendeliome' and in addition an at least superficially comprehensive exome, without the need of short-term upgrades. 
Materials and methods
DNA
DNA from peripheral blood samples was extracted using standard methods. To avoid any bias in the comparison, we included only high-quality samples without signs of degradation or protein contamination. There is no overlap between the two groups of samples.
Enrichment products
The Agilent v6 exome expands the target size from ~51 Mb (v3, v4, and v5) to 60.70 Mb. The design has been optimized with respect to bait selection and boosting based on empirical experience coming from the earlier versions to improve coverage evenness. This approach addresses the drop-off in coverage at the edges of targets, uses the up-to-date core content, and targets more genes including hard-to-capture regions. Based on this basic product, addition of UTRs for translational research, catalogue of somatic mutations in cancer (COSMIC) for cancer research, or custom content for specific applications is possible. Eight exomes were individually prepared using 200 ng of DNA, the standard protocol SureSelectXT Automated Target Enrichment for Illumina paired-end multiplexed sequencing, and the Agilent Bravo automated liquid handling platform. After validation (2200 TapeStation; Agilent Technologies, CA, USA) and quantification (Qubit System; Invitrogen, Waltham, MA, USA), two pools of four libraries each were generated.
The SeqCap EZ MedExome kit is a new whole exome solution from NimbleGen that interrogates the entire human exome with enhanced coverage of exons of disease-associated gene regions. The product has been optimized in design, empirical rebalancing, and manufacturing to increase coverage in hard-to-sequence regions to achieve a more uniform and complete exome. The target size increased from 44 Mb (v2) to 46.81 Mb with this version. A 'PLUS' configuration based on this target is also possible for up to 200 Mb user-defined content. Twelve exomes were prepared by fragmenting 1 μg of DNA using sonication technology (Bioruptor, Diagenode, Liège, Belgium) followed by end repair and adapter ligation including incorporation of Illumina TruSeq index barcodes on a Biomek FX laboratory automation workstation from Beckman Coulter ( Beckman Coulter, Brea, CA, USA). After size selection and quantification, three pools of four libraries each were subjected to enrichment using the SeqCap EZ MedExome Library kit from NimbleGen using the NimbleGen SeqCap EZ Library SR User's Guide version 3.0 protocol. The overlap between the two exome kits' target regions is shown in Figure 4 , illustrating that the smaller MedExome is not only a strict subset of the Agilent exome but there is a relevant fraction of 28 Mb, that is covered by only one of the products. Many consortia meta-analyze data sets from different studies and combine variant lists that are based on different analysis pipelines, different sequencing technologies and depth, and also different exome products. Within these approaches, bias could be better controlled using least common denominators, e.g. by analyzing only the intersection of exome targets.
Sequencing
After validation (2200 TapeStation; Agilent Technologies, CA, USA), the pools were quantified using the KAPA Library Quantification kit (Peqlab, Erlangen, Germany) and the 7900HT Sequence Detection System (Applied Biosystems, Waltham, MA, USA), and subsequently sequenced on an Illumina HiSeq 2000 sequencing instrument using a paired-end 2 × 100 bp protocol and an allocation of one pool with 4 exomes/lane.
Analysis
For data analysis, the VARBANK pipeline v.2.15 and the corresponding filter interface were used (unpublished, https://varbank.ccg. uni-koeln.de/). Raw reads were mapped to the human genome reference-build hg19 using the Burrows Wheeler Aligner (BWA) alignment algorithm with a base quality threshold of 15 for read trimming (parameter: -q 15) (Li and Durbin, 2009 ). The resulting binary alignment/map (BAM) files were further processed by Picard v1.64 (http:// broadinstitute.github.io/picard/) to mark duplicate reads and GATK v1.6 (McKenna et al., 2010) to perform local realignment around short insertions and deletions and to recalibrate the base-calling quality scores. All enrichment-performance tables were generated from these BAM files by Picard's CalculateHSMetrics function with default parameters and extracted from VARBANK's data selection sheets. The presentation of coverage of individual genes was taken from VARBANK's graphical gene coverage module, which computes the per-base coverage directly from the BAM file.
